ONCEPT, the first commercially available vaccine for the treatment of melanoma was developed by Katonah Bedford Veterinary Center’s Medical Oncology Specialist Dr. Philip Bergman in partnership with Memorial Sloan-Kettering Cancer Center and Merial. It is the first and only USDA-approved, therapeutic vaccine for the treatment of cancer " in either animals or humans " and has been shown to significantly extend survival rates of dogs suffering from stage II or stage III oral canine melanoma.
Canine oral melanoma is a common type of cancer in dogs and is the most common malignant tumor of the dog's mouth. It can also be seen in the nail and footpad. This particular cancer may be seen in any breed and is a highly aggressive cancer that frequently spreads throughout the body, including the lymph nodes, liver, lungs and kidneys. To date, the most common treatments for this form of cancer have been radiation and surgery to establish local tumor control. Canine oral melanoma, however, has a high propensity to metastasize to other parts of the body and is often resistant to chemotherapy.
Early clinical studies of ONCEPT Canine Melanoma Vaccine demonstrated significantly longer life spans, even in dogs with Stage II and Stage III canine melanoma, and led to the USDA-approval. Since then, thousands of dogs have been treated with ONCEPT and it has continued to demonstrate it is a safe, effective adjunct therapy that can significantly prolong survival times in dogs. The vaccine is administered via a Canine Transdermal Device, which delivers the vaccine without the use of a needle.
ONCEPT Canine Melanoma Vaccine is available through Katonah Bedford Veterinary Center’s Oncology Department. For questions or further information about ONCEPT, please call us at 914-241-7700. Additional information may also be found at these links: